Breaking News
May 3, 2019 - Vaping and Smoking May Signal Greater Motivation to Quit
May 3, 2019 - Dementia looks different in brains of Hispanics
May 3, 2019 - Short-Staffed Nursing Homes See Drop In Medicare Ratings
May 3, 2019 - Study of teens with eating disorders explores how substance users differ from non-substance users
May 3, 2019 - Scientists develop new video game that may help in the study of Alzheimer’s
May 3, 2019 - Arc Bio introduces Galileo Pathogen Solution product line at ASM Clinical Virology Symposium
May 3, 2019 - Cornell University study uncovers relationship between starch digestion gene and gut bacteria
May 3, 2019 - How to Safely Use Glucose Meters and Test Strips for Diabetes
May 3, 2019 - Anti-inflammatory drugs ineffective for prevention of Alzheimer’s disease
May 3, 2019 - Study tracks Pennsylvania’s oil and gas waste-disposal practices
May 3, 2019 - Creating a better radiation diagnostic test for astronauts
May 3, 2019 - Vegans are often deficient in these four nutrients
May 3, 2019 - PPDC announces seed grants to develop medical devices for children
May 3, 2019 - Study maps out the frequency and impact of water polo head injuries
May 3, 2019 - Research on Reddit identifies risks associated with unproven treatments for opioid addiction
May 3, 2019 - Good smells may help ease tobacco cravings
May 3, 2019 - Medical financial hardship found to be very common among people in the United States
May 3, 2019 - Researchers develop multimodal system for personalized post-stroke rehabilitation
May 3, 2019 - Study shows significant mortality benefit with CABG over percutaneous coronary intervention
May 3, 2019 - Will gene-editing of human embryos ever be justifiable?
May 3, 2019 - FDA Approves Dengvaxia (dengue vaccine) for the Prevention of Dengue Disease in Endemic Regions
May 3, 2019 - Why Tonsillitis Keeps Coming Back
May 3, 2019 - Fighting the opioid epidemic with data
May 3, 2019 - Maggot sausages may soon be a reality
May 3, 2019 - Deletion of ATDC gene prevents development of pancreatic cancer in mice
May 2, 2019 - Targeted Therapy Promising for Rare Hematologic Cancer
May 2, 2019 - Alzheimer’s disease is a ‘double-prion disorder,’ study shows
May 2, 2019 - Reservoir bugs: How one bacterial menace makes its home in the human stomach
May 2, 2019 - Clinical, Admin Staff From Cardiology Get Sneak Peek at Epic
May 2, 2019 - Depression increases hospital use and mortality in children
May 2, 2019 - Vicon and NOC support CURE International to create first gait lab in Ethiopia
May 2, 2019 - Researchers use 3D printer to make paper organs
May 2, 2019 - Viral infection in utero associated with behavioral abnormalities in offspring
May 2, 2019 - U.S. Teen Opioid Deaths Soaring
May 2, 2019 - Opioid distribution data should be public
May 2, 2019 - In the Spotlight: “I’m learning every single day”
May 2, 2019 - 2019 Schaefer Scholars Announced
May 2, 2019 - Podcast: KHN’s ‘What The Health?’ Bye-Bye, ACA, And Hello ‘Medicare-For-All’?
May 2, 2019 - Study describes new viral molecular evasion mechanism used by cytomegalovirus
May 2, 2019 - SLU study suggests a more equitable way for Medicare reimbursement
May 2, 2019 - Scientists discover first gene involved in lower urinary tract obstruction
May 2, 2019 - Researchers identify 34 genes associated with increased risk of ovarian cancer
May 2, 2019 - Many low-income infants receive formula in the first few days of life, finds study
May 2, 2019 - Global study finds high success rate for hip and knee replacements
May 2, 2019 - Taking depression seriously: What is it?
May 2, 2019 - With Head Injuries Mounting, Will Cities Put Their Feet Down On E-Scooters?
May 2, 2019 - Scientists develop small fluorophores for tracking metabolites in living cells
May 2, 2019 - Study casts new light into how mothers’ and babies’ genes influence birth weight
May 2, 2019 - Researchers uncover new brain mechanisms regulating body weight
May 2, 2019 - Organ-on-chip systems offered to Asia-Pacific regions by Sydney’s AXT
May 2, 2019 - Adoption of new rules drops readmission penalties against safety net hospitals
May 2, 2019 - Kids and teens who consume zero-calorie sweetened beverages do not save calories
May 2, 2019 - Improved procedure for cancer-related erectile dysfunction
May 2, 2019 - Hormone may improve social behavior in autism
May 2, 2019 - Alzheimer’s disease may be caused by infectious proteins called prions
May 2, 2019 - Even Doctors Can’t Navigate Our ‘Broken Health Care System’
May 2, 2019 - Study looks at the impact on criminal persistence of head injuries
May 2, 2019 - Honey ‘as high in sugars as table sugar’
May 2, 2019 - Innovations to U.S. food system could help consumers in choosing healthy foods
May 2, 2019 - FDA Approves Mavyret (glecaprevir and pibrentasvir) as First Treatment for All Genotypes of Hepatitis C in Pediatric Patients
May 2, 2019 - Women underreport prevalence and intensity of their own snoring
May 2, 2019 - Concussion summit focuses on science behind brain injury
May 2, 2019 - Booker’s Argument For Environmental Justice Stays Within The Lines
May 2, 2019 - Cornell research explains increased metastatic cancer risk in diabetics
May 2, 2019 - Mount Sinai study provides fresh insights into cellular pathways that cause cancer
May 2, 2019 - Researchers to study link between prenatal pesticide exposures and childhood ADHD
May 2, 2019 - CoGEN Congress 2019: Speakers’ overviews
May 2, 2019 - A new strategy for managing diabetic macular edema in people with good vision
May 2, 2019 - Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL) Due to Lack of Sterility Assurance
May 2, 2019 - Screen time associated with behavioral problems in preschoolers
May 2, 2019 - Hormone reduces social impairment in kids with autism | News Center
May 2, 2019 - Researchers synthesize peroxidase-mimicking nanozyme with low cost and superior catalytic activity
May 2, 2019 - Study results of a potential drug to treat Type 2 diabetes in children announced
May 2, 2019 - Multigene test helps doctors to make effective treatment decisions for breast cancer patients
May 2, 2019 - UNC School of Medicine initiative providing unique care to dementia patients
May 2, 2019 - Nestlé Health Science and VHP join forces to launch innovative COPES program for cancer patients
May 2, 2019 - Study examines how our brain generates consciousness and loses it during anesthesia
May 2, 2019 - Transition Support Program May Aid Young Adults With Type 1 Diabetes
May 2, 2019 - Study shows how neutrophils exacerbate atherosclerosis by inducing smooth muscle-cell death
May 2, 2019 - Research reveals complexity of how we make decisions
Novo Biosciences achieves major milestones in its new drug to treat heart disease and DMD

Novo Biosciences achieves major milestones in its new drug to treat heart disease and DMD

Novo Biosciences Inc., has achieved several major milestones in its mission of bringing its breakthrough drug candidate, trodusquemine (aka MSI-1436), to market as a potential regenerative medicine treatment for heart disease and Duchenne muscular dystrophy (DMD). Trodusquemine is a repurposed drug candidate that has already been shown to be well tolerated by patients.

“Trodusquemine holds significant potential for the treatment of some of our most devastating diseases,” said Kevin Strange, Ph.D., Novo’s CEO. “Our recent progress on the path toward clinical trials gives hope to the millions of patients who face limited treatment options.”

Novo has demonstrated that trodusquemine stimulates the regeneration of heart muscle tissue in mice after an artificially induced heart attack. Trodusquemine is the only small molecule known to stimulate regeneration of the adult mammalian heart. Heart disease is the nation’s leading cause of death, but treatment options are limited to efforts to prevent a secondary heart attack and to organ transplantation for patients who have suffered heart failure.

Voot Yin, Ph.D., Novo’s chief scientific officer, was awarded a two-year, $1.5 million Small Business Innovation Research grant in 2017 from the National Heart, Lung and Blood Institute, an institute of the National Institutes of Health (NIH), to study trodusquemine in the pig, the animal model whose heart most closely resembles that of a human. The pig study is the critical next step in moving trodusquemine into clinical trials in patients who have suffered an acute heart attack. Early results from these studies are “very encouraging,” according to Strange.

Novo has also demonstrated that trodusquemine strikingly slows heart and skeletal muscle degeneration in a mouse DMD model. DMD is a neuromuscular disease caused by mutations in the dystrophin gene. It is characterized by rapidly progressing muscle weakness and wasting due to degeneration of skeletal, smooth and cardiac muscle. DMD is irreversible and patients typically die in early adulthood. Because DMD is designated an orphan, or rare, disease, the U.S. Food and Drug Administration (FDA) offers fast-tracked approvals and other incentives to drug developers.

In a recent Pre-Investigational New Drug (PIND) meeting with the FDA, Novo was informed that its studies in the mouse DMD model provided sufficient proof-of-principle evidence of trodusquemine’s efficacy in slowing heart and skeletal muscle damage. Strange said, “We are extremely encouraged by this conclusion. We’ve got more work to do, including developing a dosing regimen for juvenile DMD patients and defining toxicity in juvenile animal models, but the path to potential clinical trials is now defined clearly.”

Trodusquemine recently attracted the attention of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), another institution within the NIH. Yin was awarded a $100,000 pilot grant to study the efficacy of trodusquemine as a potential regenerative medicine therapy for diabetic kidney disease on February 28. The one-year, proof-of-concept grant is funded by the NIDDK-sponsored DiaComp (Diabetic Complications Consortium) Pilot and Feasibility Program. DiaComp supports R&D aimed at protecting and restoring the function of organs affected by the complications of diabetes.

Novo scientists will study trodusquemine in mice with multiple, severe, kidney abnormalities that closely resemble human diabetic nephropathy, a complication of diabetes that leads to kidney disease. As with heart disease, the treatment options for chronic kidney disease are limited. More than 200,000 diabetic kidney disease patients undergo long-term dialysis or kidney transplant annually. But dialysis is costly and time consuming and the demand for donor organs for transplantation far exceeds supply.

The discovery of trodusquemine reflects Novo’s pioneering R&D strategy, which was the subject of a “marquee” article, “A Shot at Regeneration,” in the April 2019 edition of Scientific American, one of the world’s most prestigious media outlets. Scientific American is published in 14 languages and has a combined worldwide print and online circulation of nearly 20 million.

Source:

https://novobiosciences.com/

Tagged with:

About author

Related Articles